bpc157 tb500 cjc1295 ipamorelin fda warning unapproved peptides bpc-157 tb-500 cjc-1295 BPC-157 cjc-1295 ipamorelin bpc-157 tb-500 aod-9604

No FDA-approved pharmaceutical formulation exists, and the compound is not listed as a 503A bulk drug substance with positive compounding status

Legal Status CJC-1295 is currently classified as a research chemical with no formally recognized use

It is commonly examined for targeted ghrelin receptor interaction activity with reduced off-pathway signaling compared with broader secretagogue compounds

CJC-1295 raises the overall amount of GH available, while Ipamorelin drives a strong, clean pulse of release so the combination produces more GH, in a pattern that more closely mirrors how your body naturally secretes it (in pulses, mostly during deep sleep)